Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

All Oncology News

Mobocertinib Shows Superior PROs in Previously Treated EGFR Exon 20+ Metastatic NSCLC

September 8th 2021

Audrey Sternberg

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer

September 8th 2021

Mark Pegram, MD, Stanford Women's Cancer Center

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

Future Opportunities With Novel Therapies for HER2+ Breast Cancer

September 8th 2021

Giuseppe Curigliano, MD, PhD

Novel therapies that show promise in addressing treatment gaps in HER2-positive breast cancer, and exciting data that are expected to be reported on at the upcoming ESMO 2021 meeting.

R/R Metastatic HER2+ Breast Cancer Treatment Considerations

September 8th 2021

Giuseppe Curigliano, MD, PhD

Factors that impact treatment selection for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy.

HER2+ Breast Cancer: Key Takeaways From HER2CLIMB

September 8th 2021

Giuseppe Curigliano, MD, PhD

An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.

Standard of Care for R/R Metastatic HER2+ Breast Cancer

September 8th 2021

Giuseppe Curigliano, MD, PhD

Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.

Challenges in the Multidisciplinary Management of Breast Cancer

September 8th 2021

Mark Pegram, MD, Stanford Women's Cancer Center

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

Pembrolizumab Approved in China for Frontline Advanced Esophageal or GEJ Cancer

September 7th 2021

Gina Mauro

The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or gastroesophageal junction cancer.

Dr. Raghav on First-Line Treatment Options in CRC

September 7th 2021

Kanwal Raghav, MBBS, MD

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

Dr. Zhen on Advancements in Gastroenteropancreatic Neuroendocrine Tumors

September 7th 2021

David Zhen, MD

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Dr. Abdul Razak on Initial Findings With Durvalumab Plus Olaparib or Cediranib in Leiomyosarcoma

September 7th 2021

Albiruni Ryan Abdul Razak, MRCP, MBBCh

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

Dr. Ready on Selecting Between Frontline Atezolizumab and Durvalumab in ES-SCLC

September 7th 2021

Neal E. Ready, MD, PhD, Duke University Medical Center

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer.

ESMO Publishes Guidelines for the Management of Solid Tumor Brain Metastases

September 7th 2021

Caroline Seymour

The European Association of Neuro-Oncology and ESMO have released clinical practice guidelines, which provide management recommendations for the diagnosis, treatment, and follow-up of patients with solid tumor brain metastases.

Dr. Parikh on Future Research Directions in Hepatitis C-Related HCC

September 7th 2021

Neehar Parikh, MD

Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.

Dr. Llovet on Considering Safety Profiles During Treatment Selection in HCC

September 7th 2021

Josep M. Llovet, MD, PhD

Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.

See All News